Trending Topic

Illustration of the thought processes in the brain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% to exceeding 15% per 5 years.3 Ruptured IA is the primary aetiology of […]

Xavier Montalban, EAN 2021: Ofatumumab as a Treatment Option for Relapsing Multiple Sclerosis

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 9th 2021

It was a pleasure to meet with Prof. Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Vall d’Hebron, Barcelona Hospital Campus, Spain) to discuss the use of ofatumumab as a treatment option for relapsing multiple sclerosis.

The abstract entitled: ‘Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design’ was presented at the 7th Congress of the European Academy of Neurology – Virtual 2021.

Questions:

  1. Could you tell us a little about ofatumumab and its mechanism of action? (0:15)
  2. What are the advantages of ofatumumab compared to current treatment options for relapsing multiple sclerosis (RMS) in adults with active disease? (0:36)
  3. What have recent clinical trial data taught us about the efficacy and safety of ofatumumab in adults with RMS? (1:15)

Disclosures: Xavier Montalban has received speaking honoraria and/or travel expenses for participation in scientific meetings, and/or has been a steering committee member of clinical trials and/or participated in advisory boards of clinical trials in the past years with Actelion, Alexion, Bayer, Biogen, Bristol-Myers Squibb/Celgene, EMD Serono, Genzyme, Hoffmann-La Roche, Immunic, Janssen Pharmaceuticals, Medday, Merck, Mylan, Nervgen, Novartis, Sanofi-Genzyme, Teva Pharmaceutical, TG Therapeutics, Excemed, MSIF and NMSS.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch

Filmed as a highlight of the EAN Congress, Virtual 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup